论文部分内容阅读
Merritt等人最近证明,对非常小的早产儿,在出生时给予一剂外源性人表面活性剂,可以减少随后呼吸窘迫综合征(RDS)的发病率。各种类型的外源性表面活性剂,现已成功地用于治疗确诊的RDS和预防早产儿RDS的发生。这些报告着重说明本疗法在减少早产儿发病率和死亡率方面的进展。在过去20年中,通过改善产前护理和加强新生儿的监护,早产的并发症已有减少。产前护理的改善,能预防早产和改进早产儿出生时的情况。就RDS来说,改变产前护理的一个例子是给母亲用短程的皮质
Merritt et al. Recently demonstrated that administering a dose of exogenous human surfactant at birth can reduce the incidence of subsequent respiratory distress syndrome (RDS) in very small premature infants. Various types of exogenous surfactants have been successfully used to treat diagnosed RDS and prevent the development of RDS in preterm infants. These reports highlight the progress of this therapy in reducing morbidity and mortality in preterm infants. In the past two decades, the complications of preterm labor have been reduced by improving antenatal care and strengthening the custody of newborns. The improvement of prenatal care can prevent premature birth and improve prenatal birth. For RDS, one example of changing prenatal care is to give mothers short-range cortices